Skip to main content

Allergan Totally Doesn’t Need To Sell Itself To Bill Ackman’s Buddies, Says Allergan

  • Author:
  • Updated:

It’s got, like, other options. And it so did not get rejected by the cooler pharmas. Just cool it and let it figure things out. Jeez.

Allergan Inc., the maker of Botox, is telling Wall Street analysts that it has “other options” and could still tie up with another company, as it looks to defend itself from an unsolicited $46 billion offer from Valeant Pharmaceuticals International Inc….

The company cautioned that “rumors” that it was rebuffed by other potential suitors weren’t “fact,” said the Sterne Agee analysts, who said they were told it was still possible a so-called “white knight” suitor would ride to the rescue.

If Allergan decides to negotiate with Valeant, Sterne Agee said, the earliest that talks likely would happen would be in the second half of the year, following a release of clinical data for Allergan’s Darpin, a treatment for macular degeneration, an eye disease.

Allergan Tells Analysts It Has Options in Valeant Fight [WSJ MoneyBeat blog]